Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DWTX |
---|---|---|
09:32 ET | 1176 | 3.995 |
09:34 ET | 1000 | 3.9328 |
09:38 ET | 200 | 3.995 |
09:50 ET | 989 | 3.8707 |
09:54 ET | 390 | 3.8707 |
09:56 ET | 420 | 3.901 |
09:57 ET | 540 | 3.8501 |
10:17 ET | 2042 | 3.8686 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Dogwood Therapeutics Inc | 4.5M | -0.6x | --- |
Chromocell Therapeutics Corp | 4.4M | -0.4x | --- |
180 Life Sciences Corp | 4.4M | -0.2x | --- |
Hepion Pharmaceuticals Inc | 4.3M | -0.1x | --- |
Qualigen Therapeutics Inc | 4.3M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 4.3M | -1.0x | --- |
Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.58 |
EPS | $-6.51 |
Book Value | $4.94 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.